DK3237621T3 - Varianter af human alpha-galactosidase - Google Patents

Varianter af human alpha-galactosidase Download PDF

Info

Publication number
DK3237621T3
DK3237621T3 DK15874075.3T DK15874075T DK3237621T3 DK 3237621 T3 DK3237621 T3 DK 3237621T3 DK 15874075 T DK15874075 T DK 15874075T DK 3237621 T3 DK3237621 T3 DK 3237621T3
Authority
DK
Denmark
Prior art keywords
galactosidase
variants
human alpha
alpha
human
Prior art date
Application number
DK15874075.3T
Other languages
English (en)
Other versions
DK3237621T5 (da
Inventor
Nicholas J Agard
Mathew G Miller
Xiyun Zhang
Gjalt W Huisman
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Application granted granted Critical
Publication of DK3237621T3 publication Critical patent/DK3237621T3/da
Publication of DK3237621T5 publication Critical patent/DK3237621T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15874075.3T 2014-12-22 2015-12-02 Varianter af human alpha-galactosidase DK3237621T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095313P 2014-12-22 2014-12-22
US201562216452P 2015-09-10 2015-09-10
PCT/US2015/063329 WO2016105889A1 (en) 2014-12-22 2015-12-02 Human alpha-galactosidase variants

Publications (2)

Publication Number Publication Date
DK3237621T3 true DK3237621T3 (da) 2023-06-19
DK3237621T5 DK3237621T5 (da) 2024-10-14

Family

ID=56151383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15874075.3T DK3237621T5 (da) 2014-12-22 2015-12-02 Varianter af human alpha-galactosidase

Country Status (20)

Country Link
US (6) US20170360900A1 (da)
EP (2) EP3237621B1 (da)
JP (5) JP6650943B2 (da)
KR (2) KR102438885B1 (da)
AU (2) AU2015370125B2 (da)
BR (1) BR112017013300A2 (da)
CA (1) CA2970638A1 (da)
CY (1) CY1126231T1 (da)
DK (1) DK3237621T5 (da)
ES (1) ES2944889T3 (da)
FI (1) FI3237621T3 (da)
HR (1) HRP20230468T1 (da)
HU (1) HUE062016T2 (da)
IL (1) IL252479B (da)
LT (1) LT3237621T (da)
PL (1) PL3237621T3 (da)
PT (1) PT3237621T (da)
RS (1) RS64574B1 (da)
SI (1) SI3237621T1 (da)
WO (1) WO2016105889A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20180088919A (ko) 2015-12-24 2018-08-07 옥시레인 유케이 리미티드 인간 알파-n-아세틸갈락토사미니다아제 폴리펩티드
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
US11708569B2 (en) 2018-08-29 2023-07-25 University Of Copenhagen Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
MY207075A (en) * 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
BR112022003705A2 (pt) 2019-08-30 2022-05-24 Codexis Inc Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
US12565643B2 (en) 2019-09-18 2026-03-03 The Medical College Of Wisconsin, Inc. Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
TW202146648A (zh) * 2020-02-28 2021-12-16 美商克迪科思股份有限公司 人類α-半乳糖苷酶變異體

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753653A (en) 1903-09-14 1904-03-01 American Car & Foundry Co Hopper-bottom car.
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
NZ506214A (en) 1996-09-13 2002-11-26 Transkaryotic Therapies Inc Therapy for alpha-galactosidase A deficiency
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
JP2002534965A (ja) 1999-01-19 2002-10-22 マキシジェン， インコーポレイテッド 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
EP2315145B1 (en) 2002-03-01 2015-11-25 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
DK1503788T3 (da) 2002-04-25 2011-10-17 Shire Human Genetic Therapies Behandling af alpha-galactosidase A-deficiens
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009102901A1 (en) 2008-02-12 2009-08-20 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
ES2705694T3 (es) 2008-06-13 2019-03-26 Codexis Inc Método de síntesis de variantes de polinucleótidos
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US9194011B2 (en) * 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
US8876066B1 (en) 2009-12-17 2014-11-04 Progressive Fastening, Inc. Hanger with bolt closures
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
DK2865751T3 (da) * 2010-03-02 2017-01-09 Protalix Ltd Stabiliseret alpha-galactosidase og anvendelser deraf
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
JP5431428B2 (ja) 2011-09-02 2014-03-05 京楽産業．株式会社 遊技機
US20150050658A1 (en) 2012-03-15 2015-02-19 Codexix, Inc. Gene shuffling methods
WO2013156552A1 (en) * 2012-04-18 2013-10-24 Vib Vzw Means and methods for generating improved proteins
RU2695146C2 (ru) 2013-01-31 2019-07-22 Кодексис, Инк. Способы, системы и программное обеспечение для идентификации биомолекул со взаимодействующими компонентами
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
DK3049973T3 (da) 2013-09-27 2018-10-22 Codexis Inc Automatiseret screenning af enzymvarianter
US9909113B2 (en) 2014-06-12 2018-03-06 Research Foundation Of The City University Of New York Purification of recombinant alpha galactosidase A
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
EP3708661A4 (en) 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
JP2021021820A (ja) 2019-07-26 2021-02-18 富士ゼロックス株式会社 画像形成装置及びプログラム
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
TW202146648A (zh) 2020-02-28 2021-12-16 美商克迪科思股份有限公司 人類α-半乳糖苷酶變異體
KR20250052387A (ko) 2022-08-25 2025-04-18 다케다 야쿠힌 고교 가부시키가이샤 파브리병의 치료에서의 사용을 위한 조성물

Also Published As

Publication number Publication date
JP7785315B2 (ja) 2025-12-15
DK3237621T5 (da) 2024-10-14
PL3237621T3 (pl) 2023-10-30
EP3237621A1 (en) 2017-11-01
IL252479A0 (en) 2017-07-31
EP3237621A4 (en) 2018-12-05
US11278600B2 (en) 2022-03-22
NZ732171A (en) 2021-01-29
AU2015370125A1 (en) 2017-06-22
FI3237621T3 (fi) 2023-06-01
US12257291B2 (en) 2025-03-25
HUE062016T2 (hu) 2023-09-28
US20250041388A1 (en) 2025-02-06
JP6650943B2 (ja) 2020-02-19
SI3237621T1 (sl) 2023-11-30
JP2022097653A (ja) 2022-06-30
JP2018500907A (ja) 2018-01-18
JP2024150549A (ja) 2024-10-23
HRP20230468T1 (hr) 2023-11-10
WO2016105889A1 (en) 2016-06-30
KR20220123342A (ko) 2022-09-06
RS64574B1 (sr) 2023-10-31
US20200405826A1 (en) 2020-12-31
US10973888B2 (en) 2021-04-13
LT3237621T (lt) 2023-09-25
IL252479B (en) 2021-03-25
CY1126231T1 (el) 2026-02-25
JP7675443B2 (ja) 2025-05-13
KR102702200B1 (ko) 2024-09-02
US20200360489A1 (en) 2020-11-19
ES2944889T3 (es) 2023-06-26
EP4234699A1 (en) 2023-08-30
KR102438885B1 (ko) 2022-09-01
KR20170093976A (ko) 2017-08-16
US20170360900A1 (en) 2017-12-21
US20210244804A1 (en) 2021-08-12
AU2015370125B2 (en) 2022-02-03
PT3237621T (pt) 2023-07-20
US11497798B2 (en) 2022-11-15
CA2970638A1 (en) 2016-06-30
JP2019076110A (ja) 2019-05-23
AU2022202939B2 (en) 2025-03-06
EP3237621B1 (en) 2023-04-19
JP2021003129A (ja) 2021-01-14
BR112017013300A2 (pt) 2018-02-27
AU2022202939A1 (en) 2022-05-26
US12263207B2 (en) 2025-04-01
US20200360490A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3235465T3 (da) Implantat
PL3417725T3 (pl) Fajka wodna
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3331876T3 (da) Modulators of ror-gamma
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3237621T5 (da) Varianter af human alpha-galactosidase
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
DK3307267T3 (da) Behandling af multipel sklerose
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3418273T3 (da) Derivater af flavagliner
DK3151814T3 (da) Behandling af en hudlæsion
DK3113773T3 (da) Krystallinske former af grapiprant
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL254825A0 (en) Methods of treatment with taselisib
IL254502A0 (en) Solid forms of menaquinols
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
FR3024647B1 (fr) Transat de puericulture
FR3022129B1 (fr) Baignoire de puericulture
DK3200783T3 (da) Behandling af erytromelalgi